Identification and Characterization of Potential Therapeutic Candidates in Emerging Human Pathogen Mycobacterium abscessus: A Novel Hierarchical In Silico Approach

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Shanmugham, Buvaneswari ^a   Pan, Archana ^a  

^a PONDICHERRY UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFOXITIN; GATIFLOXACIN; IMIPENEM; KATG PROTEIN; MOXIFLOXACIN; TIGECYCLINE; VIRULENCE FACTOR;

AMINO ACID METABOLISM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL METABOLISM; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; CARBOHYDRATE METABOLISM; CELL FUNCTION; CELLULAR DISTRIBUTION; CHOKEPOINT ANALYSIS; COMPUTER ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DATA MINING; DRUG SCREENING; DRUG TARGETING; ENERGY METABOLISM; FATTY ACID METABOLISM; INTESTINE FLORA; MYCOBACTERIUM ABSCESSUS; NONHUMAN; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; PLASMID; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; QUALITATIVE ANALYSIS; SEQUENCE HOMOLOGY; SUBTRACTIVE CHANNEL OF ANALYSIS; XENOBIOTIC METABOLISM;

ALGORITHMS; ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES, EMERGING; COMPUTER SIMULATION; DATA MINING; DATABASES, GENETIC; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84875093869     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059126     Document Type: Article

References (117)

1. Medjahed H, Gaillard JL, Reyrat JM, (2010) Mycobacterium abscessus: a new player in the mycobacterial field. Trends Microbiol 18: 117-123.
2. Petrini B, (2006) Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS 114: 319-328.
3. Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, et al. (2009) Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 180: 896-902.
4. Chopra S, Matsuyama K, Hutson C, Madrid P, (2011) Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother 66: 1533-1536.
5. Leao SC, Tortoli E, Viana-Niero C, Ueki SY, Lima KV, et al. (2009) Characterization of mycobacteria from a major Brazilian outbreak suggests that revision of the taxonomic status of members of the Mycobacterium chelonae-M. abscessus group is needed. J Clin Microbiol 47: 2691-2698.
6. Ripoll F, Pasek S, Schenowitz C, Dossat C, Barbe V, et al. (2009) Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 4: e5660.
7. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, et al. (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416.
8. Greendyke R, Byrd TF, (2008) Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother 52: 2019-2026.
9. Cullen AR, Cannon CL, Mark EJ, Colin AA, (2000) Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am J Respir Crit Care Med 161: 641-645.
10. Nash KA, Brown-Elliott BA, Wallace RJ Jr, (2009) A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 53: 1367-1376.
11. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B, (2012) Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 67: 810-818.
12. Barh D, Tiwari S, Jain N, Ali A, Santos AR, et al. (2011) In Silico Subtractive Genomics for Target Identification in Human Bacterial Pathogens. Drug Development Research 72: 162-177.
13. Briken V, (2008) Molecular mechanisms of host-pathogen interactions and their potential for the discovery of new drug targets. Curr Drug Targets 9: 150-157.
14. Raman K, Yeturu K, Chandra N, (2008) targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis. BMC Syst Biol 2: 109.
15. Yeh I, Hanekamp T, Tsoka S, Karp PD, Altman RB, (2004) Computational analysis of Plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res 14: 917-924.
16. Vetrivel U SG, Dorairaj S, (2011) A novel in silico approach to identify potential therapeutic targets in human bacterial pathogens. HUGO J 5: 25-34.
17. Galperin MY, Koonin EV, (1999) Searching for drug targets in microbial genomes. Curr Opin Biotechnol 10: 571-578.
18. Anishetty S, Pulimi M, Pennathur G, (2005) Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis. Comput Biol Chem 29: 368-378.
19. Asif SM, Asad A, Faizan A, Anjali MS, Arvind A, et al. (2009) Dataset of potential targets for Mycobacterium tuberculosis H37Rv through comparative genome analysis. Bioinformation 4: 245-248.
20. Shanmugam A, Natarajan J, (2010) Computational genome analyses of metabolic enzymes in Mycobacterium leprae for drug target identification. Bioinformation 4: 392-395.
21. Butt AM, Nasrullah I, Tahir S, Tong Y, (2012) Comparative Genomics Analysis of Mycobacterium ulcerans for the Identification of Putative Essential Genes and Therapeutic Candidates. PLoS One 7: e43080.
22. Sarkar M, Maganti L, Ghoshal N, Dutta C, (2012) In silico quest for putative drug targets in Helicobacter pylori HPAG1: molecular modeling of candidate enzymes from lipopolysaccharide biosynthesis pathway. J Mol Model 18: 1855-1866.
23. Singh S, Malik BK, Sharma DK, (2007) Metabolic pathway analysis of S. pneumoniae: an in silico approach towards drug-design. J Bioinform Comput Biol 5: 135-153.
24. Sharma A, Pan A, (2012) Identification of potential drug targets in Yersinia pestis using metabolic pathway analysis: MurE ligase as a case study. Eur J Med Chem 57C: 185-195.
25. Sakharkar KR, Sakharkar MK, Chow VT, (2004) A novel genomics approach for the identification of drug targets in pathogens, with special reference to Pseudomonas aeruginosa. In Silico Biol 4: 355-360.
26. Kushwaha SK, Shakya M, (2010) Protein interaction network analysis-approach for potential drug target identification in Mycobacterium tuberculosis. J Theor Biol 262: 284-294.
27. Karp PD, Paley SM, Krummenacker M, Latendresse M, Dale JM, et al. (2010) Pathway Tools version 13.0: integrated software for pathway/genome informatics and systems biology. Brief Bioinform 11: 40-79.
28. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M, (2010) KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 38: D355-360.
29. Pruitt KD, Tatusova T, Maglott DR, (2007) NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 35: D61-65.
30. Baron C, Coombes B, (2007) Targeting bacterial secretion systems: benefits of disarmament in the microcosm. Infect Disord Drug Targets 7: 19-27.
31. Chen L, Xiong Z, Sun L, Yang J, Jin Q, (2012) VFDB 2012 update: toward the genetic diversity and molecular evolution of bacterial virulence factors. Nucleic Acids Res 40: D641-645.
32. Tanaka E, Kimoto T, Tsuyuguchi K, Suzuki K, Amitani R, (2002) Successful treatment with faropenem and clarithromycin of pulmonary Mycobacterium abscessus infection. J Infect Chemother 8: 252-255.
33. Shenai S, Rodrigues C, Mehta A, (2009) Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex. Int J Infect Dis 13: 46-58.
34. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, et al. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39: D561-568.
35. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403-410.
36. Zhang R, Lin Y, (2009) DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res 37: D455-458.
37. Recanatini M BG, Cavalli A, (2004) In silico antitarget screening. Drug Discovery Today: Technologies 1: 209-215.
38. Fujimura KE, Slusher NA, Cabana MD, Lynch SV, (2010) Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther 8: 435-454.
39. Rabizadeh S, Sears C, (2008) New horizons for the infectious diseases specialist: how gut microflora promote health and disease. Curr Infect Dis Rep 10: 92-98.
40. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, et al. (2004) UniProt: the Universal Protein knowledgebase. Nucleic Acids Res 32: D115-119.
41. Yu NY, Wagner JR, Laird MR, Melli G, Rey S, et al. (2010) PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics 26: 1608-1615.
42. Yu CS, Chen YC, Lu CH, Hwang JK, (2006) Prediction of protein subcellular localization. Proteins 64: 643-651.
43. Tatusov RL, Fedorova ND, Jackson JD, Jacobs AR, Kiryutin B, et al. (2003) The COG database: an updated version includes eukaryotes. BMC Bioinformatics 4: 41.
44. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, et al. (2009) STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37: D412-416.
45. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T, (2011) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27: 431-432.
46. Raman K, Chandra N, (2008) Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance. BMC Microbiol 8: 234.
47. Said MR, Begley TJ, Oppenheim AV, Lauffenburger DA, Samson LD, (2004) Global network analysis of phenotypic effects: protein networks and toxicity modulation in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 101: 18006-18011.
48. Cui T, Zhang L, Wang X, He ZG, (2009) Uncovering new signaling proteins and potential drug targets through the interactome analysis of Mycobacterium tuberculosis. BMC Genomics 10: 118.
49. Mulder N, Apweiler R, (2007) InterPro and InterProScan: tools for protein sequence classification and comparison. Methods Mol Biol 396: 59-70.
50. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39: D1035-1041.
51. Robertson JG, (2005) Mechanistic basis of enzyme-targeted drugs. Biochemistry 44: 5561-5571.
52. Chen X, Ji ZL, Chen YZ, (2002) TTD: Therapeutic Target Database. Nucleic Acids Res 30: 412-415.
53. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1128-1136.
54. Hasan S, Daugelat S, Rao PS, Schreiber M, (2006) Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput Biol 2: e61.
55. Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, et al. (2010) Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis 4: e804.
56. Dutta A, Singh SK, Ghosh P, Mukherjee R, Mitter S, et al. (2006) In silico identification of potential therapeutic targets in the human pathogen Helicobacter pylori. In Silico Biol 6: 43-47.
57. Barh D, Kumar A, (2009) In silico identification of candidate drug and vaccine targets from various pathways in Neisseria gonorrhoeae. In Silico Biol 9: 225-231.
58. Wang F, Xiao J, Pan L, Yang M, Zhang G, et al. (2008) A systematic survey of mini-proteins in bacteria and archaea. PLoS One 3: e4027.
59. Singh S, Malik BK, Sharma DK, (2007) Choke point analysis of metabolic pathways in E.histolytica: a computational approach for drug target identification. Bioinformation 2: 68-72.
60. Mathema VB, Thakuri BC, Sillanpaa M, (2011) Bacterial mer operon-mediated detoxification of mercurial compounds: a short review. Arch Microbiol 193: 837-844.
61. Brown ED, Wright GD, (2005) New targets and screening approaches in antimicrobial drug discovery. Chem Rev 105: 759-774.
62. El Zoeiby A, Sanschagrin F, Levesque RC, (2003) Structure and function of the Mur enzymes: development of novel inhibitors. Mol Microbiol 47: 1-12.
63. Stephenson K, Hoch JA, (2002) Two-component and phosphorelay signal-transduction systems as therapeutic targets. Curr Opin Pharmacol 2: 507-512.
64. Eisenreich W, Menhard B, Hylands PJ, Zenk MH, Bacher A, (1996) Studies on the biosynthesis of taxol: the taxane carbon skeleton is not of mevalonoid origin. Proc Natl Acad Sci U S A 93: 6431-6436.
65. Rohmer M, Knani M, Simonin P, Sutter B, Sahm H, (1993) Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate. Biochem J 295 (Pt 2): 517-524.
66. Cunningham FX Jr, Lafond TP, Gantt E, (2000) Evidence of a role for LytB in the nonmevalonate pathway of isoprenoid biosynthesis. J Bacteriol 182: 5841-5848.
67. Shigi Y, (1989) Inhibition of bacterial isoprenoid synthesis by fosmidomycin, a phosphonic acid-containing antibiotic. J Antimicrob Chemother 24: 131-145.
68. Lu JZ, Lee PJ, Waters NC, Prigge ST, (2005) Fatty Acid synthesis as a target for antimalarial drug discovery. Comb Chem High Throughput Screen 8: 15-26.
69. Heath RJ, White SW, Rock CO, (2001) Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res 40: 467-497.
70. Schweizer E, Hofmann J, (2004) Microbial type I fatty acid synthases (FAS): major players in a network of cellular FAS systems. Microbiol Mol Biol Rev 68: 501-517.
71. Goulding CW, Apostol MI, Sawaya MR, Phillips M, Parseghian A, et al. (2005) Regulation by oligomerization in a mycobacterial folate biosynthetic enzyme. J Mol Biol 349: 61-72.
72. Maden BE, (2000) Tetrahydrofolate and tetrahydromethanopterin compared: functionally distinct carriers in C1 metabolism. Biochem J 350 Pt 3: 609-629.
73. Swarbrick J IP, Simpsona JS, Macreadiec I, (2008) Folate Biosynthesis - Reappraisal of Old and Novel Targets in the Search for New Antimicrobials. The Open Enzyme Inhibition Journal 1: 12-33.
74. Bermingham A, Derrick JP, (2002) The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. Bioessays 24: 637-648.
75. Paterson GK, Blue CE, Mitchell TJ, (2006) Role of two-component systems in the virulence of Streptococcus pneumoniae. J Med Microbiol 55: 355-363.
76. Barrett JF, Hoch JA, (1998) Two-component signal transduction as a target for microbial anti-infective therapy. Antimicrob Agents Chemother 42: 1529-1536.
77. Fung M TA, Mybeck K, Wu JH, Hornbuckle K, Muniz E, (2001) Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceuticals markets -1960 to 1999. Drug Inf J 35: 293-317.
78. Lazarczyk DA, Goldstein NS, Gordon SC, (2001) Trovafloxacin hepatotoxicity. Dig Dis Sci 46: 925-926.
79. Moses PL, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, et al. (1999) Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 94: 1393-1396.
80. Andrade RJ, Lucena MI, Martin-Vivaldi R, Fernandez MC, Nogueras F, et al. (1999) Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatol 31: 641-646.
81. Fenner H (1989) Evaluation of the efficacy and safety of NSAIDs. A new methodological approach. Scand J Rheumatol Suppl 80: 32-39.
82. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L, (1995) Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 58: 108-117.
83. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, et al. (2010) Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 33: 503-522.
84. Thornhill M, Pemberton M, Buchanan J, Theaker E, (2000) An open clinical trial of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid. Br J Dermatol 143: 117-126.
85. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, et al. (1999) The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 281: 1728-1734.
86. Moore TJ, Cohen MR, Furberg CD, (2007) Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 167: 1752-1759.
87. Kovatcheva-Datchary P, Zoetendal EG, Venema K, de Vos WM, Smidt H, (2009) Tools for the tract: understanding the functionality of the gastrointestinal tract. Therap Adv Gastroenterol 2: 9-22.
88. Neish AS, (2009) Microbes in gastrointestinal health and disease. Gastroenterology 136: 65-80.
89. Hooper LV, Bry L, Falk PG, Gordon JI, (1998) Host-microbial symbiosis in the mammalian intestine: exploring an internal ecosystem. Bioessays 20: 336-343.
90. Xu J, Gordon JI, (2003) Honor thy symbionts. Proc Natl Acad Sci U S A 100: 10452-10459.
91. Savage DC, (1986) Gastrointestinal microflora in mammalian nutrition. Annu Rev Nutr 6: 155-178.
92. Guarner F, Malagelada JR, (2003) Gut flora in health and disease. Lancet 361: 512-519.
93. Butt AM, Tahir S, Nasrullah I, Idrees M, Lu J, et al. (2012) Mycoplasma genitalium: a comparative genomics study of metabolic pathways for the identification of drug and vaccine targets. Infect Genet Evol 12: 53-62.
94. Peterson JW (1996) Bacterial Pathogenesis. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston (TX).
95. Dong J, Horvath S, (2007) Understanding network concepts in modules. BMC Syst Biol 1: 24.
96. Brown BM, Wang Z, Brown KR, Cricco JA, Hegg EL, (2004) Heme O synthase and heme A synthase from Bacillus subtilis and Rhodobacter sphaeroides interact in Escherichia coli. Biochemistry 43: 13541-13548.
97. Tam R, Saier MH Jr, (1993) Structural, functional, and evolutionary relationships among extracellular solute-binding receptors of bacteria. Microbiol Rev 57: 320-346.
98. Bitter W, Houben EN, Bottai D, Brodin P, Brown EJ, et al. (2009) Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog 5: e1000507.
99. Teutschbein J, Schumann G, Mollmann U, Grabley S, Cole ST, et al. (2009) A protein linkage map of the ESAT-6 secretion system 1 (ESX-1) of Mycobacterium tuberculosis. Microbiol Res 164: 253-259.
100. Stanley SA, Raghavan S, Hwang WW, Cox JS, (2003) Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc Natl Acad Sci U S A 100: 13001-13006.
101. Brodin P, Majlessi L, Marsollier L, de Jonge MI, Bottai D, et al. (2006) Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect Immun 74: 88-98.
102. Pearson MA, Michel LO, Hausinger RP, Karplus PA, (1997) Structures of Cys319 variants and acetohydroxamate-inhibited Klebsiella aerogenes urease. Biochemistry 36: 8164-8172.
103. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, et al. (2001) Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 104: 901-912.
104. Gayathri R, Therese KL, Deepa P, Mangai S, Madhavan HN, (2010) Antibiotic susceptibility pattern of rapidly growing mycobacteria. J Postgrad Med 56: 76-78.
105. Park S, Kim S, Park EM, Kim H, Kwon OJ, et al. (2008) In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci 23: 49-52.
106. Prayle A, Watson A, Fortnum H, Smyth A, (2010) Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 65: 654-658.
107. Rafii F, Sutherland JB, Cerniglia CE, (2008) Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag 4: 1343-1358.
108. Kager L, Malmborg AS, Nord CE, Pieper R, (1982) The effect of short-term cefoxitin prophylaxis on the colonic microflora in patients undergoing colorectal surgery. Infection 10: 338-340.
109. Norrby SR, Newell PA, Faulkner KL, Lesky W (1995) Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 36 Suppl A: 207-223.
110. Zhanel GG, Simor AE, Vercaigne L, Mandell L, Canadian Carbapenem Discussion G, (1998) Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis 9: 215-228.
111. Job ML, Dretler RH, (1990) Seizure activity with imipenem therapy: incidence and risk factors. DICP 24: 467-469.
112. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, et al. (2006) Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 61: 895-902.
113. Nord CE, Sillerstrom E, Wahlund E, (2006) Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 50: 3375-3380.
114. Samonis G, Kofteridis DP, Maraki S, Alegakis D, Mantadakis E, et al. (2005) Levofloxacin and moxifloxacin increase human gut colonization by Candida species. Antimicrob Agents Chemother 49: 5189.
115. Miravitlles M, (2007) Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2: 191-204.
116. Andrade RJ, Tulkens PM, (2011) Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother 66: 1431-1446.
117. Henann NE, Zambie MF, (2001) Gatifloxacin-associated acute hepatitis. Pharmacotherapy 21: 1579-1582.